Qin Xiaoling, Director-General of Department of Science, Technology and International Cooperation of National Medical Products Administration, attended the opening ceremony of the forum and delivered a speech
date：2024-02-22 14:31:10 views：
On September 6th, the 6th Belt and Road Forum for Traditional Chinese Medicine Development, as a summit forum of the 2023 China International Fair for Trade in Services, was successfully held at the Beijing National Convention Center. The forum was co-hosted by the National Administration of Traditional Chinese Medicine, the Chinese People's Association for Friendship with Foreign Countries, and the People’s Government of Beijing Municipality, with the theme: 'Deepening Cooperation of Belt and Road Traditional Chinese Medicine Development and Jointly Creating a Global Community of Health for All'. Officials from Chinese and foreign government departments, representatives from international organizations, academicians from the Academy of Engineering, Nobel laureates, and leaders from the political consultative conferences of 10 provinces including Guangdong, Zhejiang, Shaanxi, Yunnan, Jiangxi, Fujian, Sichuan, Gansu, Hebei, and Henan, alongside diplomats from 20 embassies stationed in China from countries such as South Africa, Israel, Belarus, Pakistan, Ethiopia, Zimbabwe, Zambia, Cape Verde, Liberia, Sri Lanka, Uruguay, and Cuba, as well as representatives from over 400 enterprises, participated in the event. Qin Xiaoling, Director-General of Department of Science, Technology and International Cooperation of National Medical Products Administration, attended the opening ceremony of the forum and delivered a speech.
Qin Xiaoling, Director-General of Department of Science, Technology and International Cooperation of National Medical Products Administration, attended the opening ceremony of the forum and delivered a speech
Esteemed Commissioner Yu Yanhong, Vice President Li Xikui, Deputy Mayor Jin Wei, Vice Chairman Zhao Fengtao, leaders, ladies and gentlemen, good morning!
I am honored to participate in the 6th Belt and Road Forum for Traditional Chinese Medicine Development on behalf of Deputy Commissioner Zhao Junning and to extend greetings to the conference.
Traditional Chinese medicine (TCM) is a treasure of the Chinese nation. The National Medical Products Administration, in implementing the directives of President Xi Jinping on further developing TCM, has established a review and approval system tailored to TCM’s characteristics. We have built a comprehensive regulatory system from standardized cultivation of medicinal materials to clinical application, established a TCM standard system centered around the Chinese Pharmacopoeia, expanded the research base and disciplinary development of TCM regulation, contributing ‘Chinese wisdom’ to the construction of a global community of health for all.
First, we adhere to a systematic concept to firmly establish a safety baseline for the high-quality development of TCM. Addressing the long chain and multiple stages of TCM, we continuously strengthen the quality and safety supervision of each link in TCM. In recent years, we have organized centralized governance, special rectifications, production inspections, and cause-based inspections for TCM, enhancing online sales supervision, strengthening sampling and adverse reaction monitoring, promoting GAP demonstration construction, urging TCM marketing authorization holders to conduct post-marketing evaluations, and revising safety information in instructions. Building on the foundation of special rectification for TCM safety, we further carry out actions to consolidate and enhance TCM safety. The whole industry chain and lifecycle management of TCM have achieved remarkable results, with the quality pass rate of TCM decoction pieces rising from 88% in 2018 to around 97% now, and the overall pass rate of proprietary Chinese medicines has been steadily above 98%.
Second, we adhere to reform and innovation to inject new vitality into the high-quality development of TCM. Innovation is the primary driving force for development. We continue to deepen the reform of the TCM review and approval system, issuing ‘Implementation Opinions on Promoting the Inheritance and Innovation Development of TCM’ and ‘Several Measures on Further Strengthening the Scientific Supervision of TCM to Promote the Inheritance and Innovation Development of TCM’. Respecting the characteristics and development patterns of TCM, we adjust the TCM registration classification, innovatively build a TCM registration review evidence system combining TCM theory, human experience, and clinical trials, optimize technical requirements, and issue a series of TCM technical guidance principles. Supported by these policies, the number of clinical trials and marketing applications for TCM new drugs in China has increased simultaneously, with double-digit growth in the past two years. A batch of TCM new drugs with precise therapeutic positioning and significant clinical value have been approved for marketing, meeting the public's clinical medication needs well.
Third, we strengthen the construction of scientific regulatory capacity to provide new support for the high-quality development of TCM. We implement the China Drug Regulation Science Action Plan, completing two batches of key TCM projects and preparing for the third batch. We actively promote the transformation of scientific achievements from the Drug Regulation Science Action Plan, timely applying new regulatory tools, methods, and standards adapted to the development of the pharmaceutical industry and scientific and technological progress to practice, effectively improving regulatory efficiency. Simultaneously, we fully leverage the role of high-end think tanks, establishing a TCM management strategic decision-making expert advisory committee comprising academicians, national medical masters, and senior experts in TCM, enhancing the scientific and authoritative nature of major TCM regulatory decisions.
Fourth, we continuously deepen international cooperation to expand new horizons for the high-quality development of TCM. China’s general health cannot be separated from the world, and the global health industry also needs China’s active participation. China has become a member of the WHO International Regulatory Cooperation for Herbal Medicines (IRCH) and the Western Pacific Regional Forum for the Regulation of Herbal Medicines (FHH). Through these platforms, we share our experience in developing TCM standards, strengthening cooperation and exchanges with regulatory agencies and international organizations, deeply participating in the revision of relevant standards and rules, deepening traditional herbal medicine regulatory cooperation, conducting international traditional herbal medicine registration and regulatory training, encourage domestic enterprises and research institutions to organize international multicenter clinical trials and foreign market registrations for TCM, and enter the international market, effectively enhancing China’s capacity to participate in global health governance.
Ladies and gentlemen! Currently, the ‘Healthy Silk Road’ has become an important public good provided by China for deepening global health cooperation, and TCM has become a new highlight of the Belt and Road Initiative with tremendous potential. The National Medical Products Administration will deeply study and implement the spirit of the 20th National Congress of the Communist Party of China, inherit the essence, maintain integrity, and innovate, continuously promote the high-quality development of TCM in inheritance and innovation, further enhance the level of exchange and cooperation in TCM among Belt and Road co-construction countries, and inject stronger momentum into the construction of a global community of health for all.
Finally, I wish the forum a complete success! Thank you!